www.horizonscan.nl gebruikt cookies om het gebruik van de website te analyseren en het gebruiksgemak te verbeteren. Lees meer over
cookies
op www.rijkshuisstijl.nl
Sluiten
You are here:
Horizonscan geneesmiddelen
Medicines
Search the site
Search
Published on
12 June 2018
Compact view
Extended view
Grouped by indication
Grouped by status
Grouped by reason of inclusion in Horizonscan Geneesmiddelen
Grouped by submission date
Grouped by expected registration date
Grouped by manufacturer
Grouped by mechanism of action
Grouped by particularity
Grouped by registration phase
Grouped by domain
Ungrouped
Filters
Sluit
Registration
Show ATMPs only
Show Orphan drugs only
Mechanism of action
Any mechanism of action
Unknown
Alkylating agent
Allergen
Allogeneic modified cell therapy
Amino acid
Anesthetic
Angiogenesis inhibitor
Antiandrogen
Antibiotic
Antibody-drug conjugate
Anticoagulant
Antifungals
Antihistamine
Antioxidant
Antisense oligonucleotide
Autologous modified cell therapy
Bcl-2 inhibitor
BET inhibitor
Calcineurin inhibitor
Cancer vaccine
Cannabinoid
CAR-T therapy
CDK4 / 6 tyrosine kinase inhibitor
CFS1R inhibitor
CGRP-directed antibody
Chelating agent
Coagulant
Combination therapy
Complement inhibitor
Corticosteroid
CTLA-4 antibody
Cytostatic
Disinfectant
Enzyme
Enzyme inhibitor
Enzyme replacement therapy
Gene therapy
GLP-1 receptor agonist
Glucagon analogue
Growth factor
HIV inhibitor
Hormonal therapy
Immunostimulation
Immunosuppression
Insulin preparation
Interferon inhibitor
Interleukin inhibitor
Ion channel blocker
JAK tyrosine kinase inhibitor
LABA / ICS
LABA / LAMA
LABA / LAMA / ICS
LAMA
MEK kinase inhibitor
Neurotoxin
Neurotransmitter
Oncolytic adenovirus
Other
Other, see general comments
PARP inhibitor
PD-1 / PD-L1 inhibitor
Proteasome inhibitor
Protein chaperone
Receptor agonist
Receptor antagonist
Serine / threonine kinase inhibitor
SGLT inhibitor
Small interfering RNA (siRNA)
Sodium channel blocker
Thrombin inhibitor
TNF-alpha inhibitor
Tyrosine kinase inhibitor
Vasodilator
Virus inhibitor
Budgetting framework
Any budgetting framework
Unknown
Extramural (GVS)
Intermural (MSZ)
Particularity
Any particularity
Unknown
New medicine with Priority Medicines (PRIME)
New therapeutical formulation
Reason of inclusion
New medicines
Indication extensions
IND
Biosimilars / generics
BS
G
Download
ALS
Masitinib
Allergy
Olopatadine / mometasone
Antithrombotic medications
Andexanet alfa
Betrixaban
Ciraparantag
Dabigatran etexilaat
Rivaroxaban
Asthma
Benralizumab
Dupilumab
Tiotropium
Tralokinumab
Bacterial infections
Amoxicilline / omeprazol / rifabutin
Cadazolid
Eravacycline
Iclaprim
Imipenem / Relebactam
Liposomaal amikacine
Meropenem / vaborbactam
Nemonoxacin
Omadacycline
Ozenoxacine
Bladder cancer
Atezolizumab
Durvalumab
Durvalumab / Tremelimumab
Ramucirumab
Bowel diseases
Alicaforsen
Pouchitis
Ulcerative colitis
Darvadstrocel
Etrolizumab
Ulcerative colitis
Ziekte van Crohn
Masitinib
Remestemcel-L
Rifaximin
Tenapanor
Tofacitinib
Ustekinumab
Brain cancer
Brain cancer vaccine
Depatuxizumab mafodotin
Breast cancer
Abemaciclib
Atezolizumab
Neratinib
Olaparib
Pembrolizumab
Pertuzumab
Ribociclib
Breast cancer, advanced metastatic, HR+ and HER2-, in combination with fulvestrant, postmenopausal women and men, 1L en 2L.
Breast cancer, advanced metastatic, HR+ and HER2-, in combination with tamoxifen and goserelin or a non-steroidal aromatase inhibitor (NSAI) and goserelin, premenopausal women.
Talazoparib
Veliparib
COPD
Benralizumab
Fluticasone furoate / umeclidinium (bromide) / vilanterol (trifenatate)
Formoterol / glycopyronium / budesonide
Glycopyrrolate / formoterol
Mepolizumab
Revefenacin
Cardiovascular diseases
Avacopan
Colon cancer
Atezolizumab
Nivolumab
Cystic fibrosis
Ivacaftor
Tezacaftor / ivacaftor
Dementia
Leuco-methylthioninium
Alzheimer’s disease, mild-to-moderate.
Dementia, behavioural variant frontotemporal.
Diabetes
Dapagliflozine
Empagliflozine
Ertugliflozin
Ertugliflozin / metformin
Ertugliflozin / sitagliptin
Exenatide
Diabetes type 2
Diabetes type 2
Glibenclamide
Semaglutide
Sotagliflozin
Epilepsy
Vigabatrin
Eye disorders
Brolucizumab
Cenegermin
Ciclosporin
Keratoconjunctivitis sicca (or dry eye disease), moderate-to-severe and specifically in patients with atopic keratoconjunctivitis.
Treatment of severe vernal keratoconjunctivitis in children from 4 years of age and adolescents.
Eculizumab
KPI-121
Dry eye disease.
Ocular pain and inflammation. Om te gebruiken na oogchirurgie.
Latanoprostene bunod
Lifitegrast
Mercaptamine
RGN-259
Voretigene neparvovec
Graft versus Host
Ibrutinib
Itacitinib
Head and neck cancer
Afatinib
Brilacidin
Durvalumab
Squamous cell carcinoma of the head and neck, 1L PDL 1.
Squamous cell carcinoma of the head and neck, 2L
Durvalumab / Tremelimumab
Head and neck (or upper airways tract) cancers; squamous cell carcinoma of head or neck (SCCHN), 2L Durvalumab monotherapy in PDL1-positive tumours or in combination with Tremelimumab for PDL1-negative tumours.
Squamous cell carcinoma of the head and neck, 1L PDL 1
Pembrolizumab
Headache
Eptinezumab
Erenumab
Fremanezumab
Galcanezumab
Prophylactic treatment of migraine headache.
Clusterhoofdpijn
Lasmiditan
Hemostasis promoting medication
Damoctocog alfa pegol
Emicizumab
Hemlibra is geïndiceerd voor de routineprofylaxe van bloedingen bij patiënten met hemofilie A met remmers tegen factor VIII. Hemlibra kan bij alle leeftijdsgroepen worden gebruikt.
Hemlibra is geïndiceerd voor de routinematige profylaxe van bloedingen bij patiënten met hemofilie A zonder remmers tegen factor VIII.
Eptacog beta (activated)
Rurioctocog alfa pegol
Vonicog alfa
Hormonal disorders
Abaloparatide
Elagolix
Enclomifene
Glucagon
Macimorelin
Osilodrostat
Prasterone
Recombinant parathyroid hormone
Tenapanor
Infectious diseases other
Isavuconazole
Kidney cancer
Atezolizumab
Avelumab
Ipilimumab
Rocapuldencel-T
Sunitinib
Leukemia
Blinatumomab
Adults with minimal residual disease (MRD) positive B-cell precursor acute lymphoblastic leukaemia (ALL).
Relapsed / Refractory Ph+ Adult Acute Lymphoblastic Leukemia (ALL).
Relapsed / Refractory precursor-B Acute Lymphoblastic Leukemia (ALL) in children.
Bosutinib
Cytarabine / daunorubicin (liposomaal)
Dasatinib
Indicated for the treatment of paediatric patients with newly diagnosed Ph+ CML in chronic phase (Ph+ CML-CP) or Ph+ CML-CP resistant or intolerant to prior therapy including imatinib.
Pediatric ALL
Duvelisib
Enasidenib
Eryaspase (Asparaginase)
Gemtuzumab ozogamicin
Gilteritinib
Ibrutinib
1L Chronic Lymphatic Leukemia young and fit patients
Chronische Lymfatische Leukemie 1L, non-fit icm obinutuzumab
Idelalisib
Imetelstat
Inotuzumab ozogamicin
Sapacitabine
Tamibarotene
Tisagenlecleucel-T
Venetoclax / cytarabine
Venetoclax in combinatie met rituximab
Lipid-lowering medications
Alirocumab
Evolocumab
Volanesorsen (sodium)
Liver cancer
Cabozantinib
Nivolumab
Ramucirumab
Liver diseases
Obeticholic acid
Lung cancer
Atezolizumab
Tecentriq is als monotherapie geïndiceerd voor de behandeling van volwassen patiënten met lokaal gevorderde of gemetastaseerde niet-kleincellige longkanker (NSCLC) na eerdere behandeling met chemotherapie. Patiënten met EGFR-activerende mutaties of ALK-positieve mutaties moeten ook doelgerichte behandeling hebben ontvangen voor ze Tecentriq krijgen.
First line treatment of advanced non-squamous non-small cell lung cancer (NSCLC). Combination of Tecentriq, Avastin and chemotherapy.
For the 1L treatment of patients with metastatic, squamous NSCLC in combination with chemotherapy
Avelumab
Brigatinib
Durvalumab
Non-small cell lung cancer (NSCLC) stage III, unresectable.
Non-small cell lung cancer (NSCLC), 1L monotherapy
Durvalumab / Tremelimumab
Lorlatinib
Lurbinectedin
Osimertinib
Rociletinib
Rovalpituzumab tesirine
Veliparib
Lung other
Alpha-1 antitrypsin
Mepolizumab
Nintedanib
Pirfenidone
Rituximab
Sirolimus
Lymphoma
Axicabtagene ciloleucel
Brentuximab vedotin
Ibrutinib
Follicular lymphoma (FL), relapsed / refractory.
Mantle cell lymphoma (MCL), 1L.
Marginal zone lymphoma (MZL), relapsed / refractory.
Non-germinal center B-cell-like (non-GCB) diffuse large B-cell lymphoma (DLBCL), 1L.
Waldenstrom's macroglobulinemia (WM) in combinatie met Rituximab
Lenalidomide / Rituximab
Mogamulizumab
Tisagenlecleucel-T
Mesothelioma
Nintedanib
Nivolumab
Metabolic diseases
Asfotase alfa
Burosumab
Cerliponase alfa
Chenodeoxycholzuur
Cyclodextrine (Hydroxypropyl betadex)
Ibiglustat
Idursulfase-IT
Kaliumcitraat / kaliumwaterstofcarbonaat
Metreleptin
Neod001
Patiromer
Pegvaliase
Sebelipase alfa
Sodium benzoate
Sodium zirconium cyclosilicate
Velmanase alfa
Vestronidase alfa
Multiple Myeloma
Carfilzomib
Daratumumab
Multipel myeloom frontline behandeling in combinatie met Rd, non fit voor ASCT.
Multipel myeloom frontline behandeling in combinatie met VMP non fit voor ASCT.
Multipel myeloom frontline behandeling voor ASCT in combinatie met VTD.
Denosumab
Lenalidomide / bortezomib / dexamethason
Plitidepsin
Pomalidomide / bortezomib / dexamethason
Multiple sclerosis
ALKS8700
Cladribine
Masitinib
Ocrelizumab
Volwassen patiënten met actieve relapsing multiple sclerose (RMS) die is gedefinieerd door klinische of beeldvormende kenmerken.
Volwassen patiënten met vroege primair progressieve multiple sclerose (PPMS) gebaseerd op de ziekteduur, mate van invaliditeit en beeldvormende kenmerken die typerend zijn voor ontstekingsactiviteit.
Ozanimod
Siponimod
Muscular diseases
Adeno-associated viral vector serotype 9 containing the human SMN gene (AVXS-101)
Botulinum A toxin
Lower limb spasticity (LLS), in adults post stroke or traumatic brain injury (TBI).
Lower limb spasticity (LLS), post stroke.
Eteplirsen
Ibudilast
Idebenone
Mexiletine HCl
Nusinersen
Valbenazine
Neuroendocrine cancer
Lutetium (177Lu) oxodotreotide
Selumetinib
Telotristat etiprate
Neurological disorders other
Botulinum A toxin
CM-AT / CM-4612
Esketamine
Inotersen
Patisiran
Oncology other
Entolimod
Larotrectinib
Pembrolizumab
Other chronic immune diseases
Budesonide
Forigerimod (Rigerimod)
Lanadelumab
Lesinurad / allopurinol
Tocilizumab
Triamcinolone
Other hematology
Donor-derived T-lymphocyte enriched leukocyte preparation depleted ex vivo of host-alloreactive T cells.
Fedratinib
Myelofibrosis
Polycythemia vera
Lusutrombopag
Pacritinib
Romiplostim
Ropeginterferon alfa-2b
Treosulfan
Other medication for cardiovascular diseases
Allogenic immunomodulatory progenitor cells
Canakinumab
Ticagrelor
Valsartan / sacubitril
Other metabolism and Endocrinology
Romosozumab
Other non-oncological hematological medications
Avatrombopag
Caplacizumab
Ferumoxytol
Rivipansel Sodium
Ovarian cancer
Avelumab
Niraparib (tosylate monohydrate)
Olaparib
Lynparza is geïndiceerd als monotherapie voor de onderhoudsbehandeling van volwassen patiënten met platinasensitief recidief hooggradig epitheliaal ovarium, tuba- of primair peritoneaal carcinoom die een respons (volledige of partiële) vertonen op platinabevattende chemotherapie.
BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy.
Olaparib / Cediranib
Rucaparib
Veliparib
Pain
Oxycodon ER
Pancreatic cancer
Olaparib
Parkinson's
Pimavanserin
Prostate cancer
Apalutamide
Chemo-naieve gemetastaseerde castratie resistente prostaat carcinoom, in combinatie met Abiraterone.
Gemetastaseerde hormoon-gevoelige, hoog-volume prostaat carcinoom.
Niet-gemetastaseerde castratie resistente prostaat carcinoom.
Darolutamide
Enzalutamide
Adult men with newly diagnosed high risk metastatic hormone sensitive prostate cancer (mHSPC) in combination with androgen depreviation therapy.
Niet gemetastaseerde castratieresistente prostaatkanker (M0CRPC).
Olaparib
Padeliporfin
Psychiatry
Brexpiprazole
Cariprazine
Schizofrenie bij volwassenen.
Bipolaire depressie
Esketamine
Lurasidone
Rheumatism
Infliximab SC
Ixekizumab
Alleen of in combinatie met methotrexaat geïndiceerd voor de behandeling van actieve artritis psoriatica bij volwassen patiënten die één of meer therapieën met disease-modifying antirheumatic drugs (DMARDs) niet verdroegen of daar ontoereikend op reageerden.
Axiale Spondyloartritis
Tofacitinib
Upadacitinib
Skin cancer
Binimetinib
Cemiplimab
Dabrafenib / Trametinib
Encorafenib
LN-144 (TIL)
Nivolumab
Pembrolizumab
Skin diseases
Bimekizumab
Certolizumab pegol
Dupilumab
Dupixent is geïndiceerd voor de behandeling van matig-ernstige tot ernstige atopische dermatitis bij volwassenen die in aanmerking komen voor een systemische behandeling.
Atopische dermatitis bij kinderen
Guselkumab
Nemolizumab
Risankizumab
Tildrakizumab
Tralokinumab
Ustekinumab
Sleep disorders
Melatonin
Pitolisant
Tasimelteon
Stomach cancer
Atezolizumab
Masitinib
Nivolumab
Pembrolizumab
Viral infections other
Bictegravir / emtricitabine / tenofovir alafenamide fumaraat
CMV DNA vaccin (ASP0113)
Dolutegravir / rilpivirine
Doravirine
Doravirine / lamivudine / tenofovir disoproxil (fumarate)
Fostemsavir
Letermovir
Peramivir
Recombinant zoster vaccin
Sofosbuvir / velpatasvir / voxilaprevir
Zanamivir
Naar boven
National Health Care Institute
Login
Understanding of expected market entry
of innovative medicines
Service
Contact
Downloads
Export
About this site
Copyright
Privacy
Cookies
Toegankelijkheid
Kwetsbaarheid melden
Over de Horizonscan
About the Horizon Scan
Nederlands
English